Key Takeaways
- Seasonal softness, structural confidence: Volume grew 7% despite Q2 being a low-volume season and heavy rains disrupting paints, lubes, and ice cream/yogurt packaging. Management expects a Q4 rebound and maintained its ~12% volume growth target.
- Pharma is the breakout story: Pharma packaging revenue jumped 45% QoQ to ₹10-plus crores, putting the company on track to exceed its ₹35 crore FY26 target. Two strategic clients with ₹10+ crore annual potential each began ordering.
- Food & FMCG realizations under pressure: Realizations dropped from ₹330-₹340/kg to ~₹295/kg over several years due to regional competition and freight disadvantages from a centralized Hyderabad base. The new Panipat plant is the countermeasure.
- EBITDA per kg dipped on operating leverage: Fell from ₹41 to ₹39 QoQ as capacity utilization dropped from 74% to 63%, driven by rains and a GST-announcement order lull. Management expects H2 recovery to ₹40-₹41.
- What to watch next quarter: Whether pharma sustains its ₹10+ crore quarterly run rate, the pace of Panipat's ramp-up with its one major signed contract, and whether paint volumes return toward the 4,800-5,000 ton level as rains subside.
Pharma Packaging: The New Growth Engine
- Q2 inflection: Pharma sales reached ₹10-plus crores, up from ₹7-plus crores in Q1, driven by EV tubes, caps, and bottles. Canisters have just started picking up.
- Client momentum: More than 20-25 active clients with 5-6 additions this quarter. Prominent new names Laurus and MSN began small commercial orders; both have large potential and offer local advantage. Over 50 clients have visited facilities; 30 have approved facilities but are still in trial or commercial negotiation stages.
- Revenue trajectory: FY26 target of ₹35 crores now likely to be exceeded at ₹35-₹37 crores. FY27 target set at ₹55-₹60 crores, with FY28 aiming for another 40%-50% growth toward ₹80-₹90 crores. Long-term aspiration of ₹150-₹180 crores in 5 years.
- Capacity build-out: Acquired 2.5 acres adjacent to Sultanpur for ₹11 crores in Q1 for a Greenfield pharma facility. Plant approval expected December, construction starts December-January, operational by July-August next year. Existing capacity to step up to ~2,500 tons during next financial year.
- Product range expanding: More than 40 bottle varieties, 8-10 cap varieties. New products include eye droppers, cough drop caps, and shell-resistant caps. The biggest single client represents ~10% of pharma sales (EV tubes); 7-8 decent-size bottles and caps clients run at ₹25-₹30 lakhs per month each.
Rao: "This year itself we may cross our Rs. 35 crores target. Because we are almost 10 plus in this quarter. So, even if you continue the same trend in the next 2 quarters, because the new product addition will be happening in Q4... even assuming we continue to do Rs. 10 crores for next 2 quarters, we will end up with Rs. 35-Rs. 37 crores, which is above our target of 35."
Paint & Lubes: Weather-Hit but Recoverable
- Paint volumes: Q2 paint turnover grew only 2.6% with 3% volume growth, a sharp deceleration from Q1's 21% growth. Heavy rains suppressed demand for paints, ice creams, and yogurts. Management confident of a return to 4,800-5,000 tons per quarter once rains subside, with pent-up demand expected as washed-away paint creates replacement need.
- Grasim (Birla Opus) outperformed: Grew 17% in value in Q2 while the rest of the paint segment was negative or flat. Full-year expectation of 6,000-6,500 tons from Grasim. Asian Paints volumes were flattish, up or down 2%-3%.
- Lubes structural skepticism: Lubricants down 13% YoY due to monsoon impacting goods movement. Management is skeptical about a return to the 2,000+ tons quarterly run rate because improving fuel mileage per liter means lubricant consumption may not grow in tandem with economic activity. GST reduction might help movement of goods.
Rao: "For paints, I am confident. But for lubes, I am skeptical because the movement of goods will pick up with the GST reduction and that might drive lubes growth. As I said, lubricants are coming out with more and more mileage per liter. So, definitely, though the economy is increasing in terms of movement of goods, the lubricant consumption may not grow in tandem."
Food & FMCG: Pricing Pressure Meets Geographic Expansion
- Realization erosion: F&F realizations have declined from ₹330-₹340/kg in FY22 to ~₹295/kg, with a marginal further dip from ~₹309/kg in Q1 to ~₹300/kg in Q2. The root cause is competition from small regional players, while Mold-Tek's centralized Hyderabad operations create freight cost and time disadvantages when supplying nationwide.
- Panipat as the fix: The new Panipat plant has begun production and signed one major contract (details undisclosed) that should add at least ₹4-₹5 crores turnover next financial year. Molds are under manufacturing, operational from February. Several small and medium orders are also coming in. Management expects North to contribute handsomely in FY27.
- Growth confidence intact: H1 F&F growth was 17%, and management is confident of maintaining 15%-20% growth. Steady-state EBITDA per kg for F&F is now ~₹70-₹75, down from ~₹75-₹80 earlier, a ₹3-₹4/kg decline from competition that volume growth through the North plant is expected to offset.
- Sweet pack contracts: Signed a couple of decent contracts with dairies in the Delhi NCR area; these should add numbers from February onwards.
Rao: "There is definitely some pressure in competition coming up in corners of food and FMCG sector... we being all centralized in Hyderabad and supplying all the products across the country only from Hyderabad have the disadvantage of both time delays and freight costs. So, now that Panipat started and we already captured couple of big clients in that region, I am confident next season, we will be able to command and get back our numbers."
Margins & Operating Metrics
- EBITDA per kg QoQ decline: Dropped from ₹41 to ₹39 as capacity utilization fell from 74% in Q1 to 63% in Q2. Two drivers: severe rains suppressing demand across multiple segments, and a GST-announcement-induced order lull in September before the new rate took effect. Overheads rose on the lower base.
- H2 recovery expected: Management confident of delivering ₹40-₹41 EBITDA per kg in H2, up from ₹37.6 for the full previous year, a 6%-7% improvement. H1 EBITDA margin growth was 8.3%. The recovery assumes normalization of capacity utilization as seasonal headwinds fade and pharma/F&F growth fill the gap.
- IML integration benefits: The Jeedimetla unit was closed in July-August, machinery shifted to Sultanpur, and operations started August-September. Cost benefits in IML consumables (~₹22/kg cost base, ~₹1/kg benefit expected) will accrue from Q3-Q4, with fuller impact in FY27. IML and other label HDL volume share improved marginally to 75.11% in Q2.
- Realization mix shift: As pharma and food & FMCG increase their share of the revenue mix, per-kg realization should improve, though this depends partly on raw material pricing.
Rao: "No, I said our guidance is Rs. 40-Rs. 42 depending upon the growth. But with the tepid growth in Q2, we feel we will still do Rs. 40.7, may be Rs. 41 at the best."
Capacity, Capex & Competitive Position
- Capex moderating: ₹60 crores completed so far; annual run rate of ₹30-₹35 crores additional expected, taking full-year capex to ~₹100-₹105 crores, down from a ~₹140 crore average over the last three years. Maintenance capex runs ~₹35-₹40 crores per annum; the balance is for additional pharma capacity and balancing capacities across ABG plants.
- Capacity utilization: Optimal is 100% but 75%-80% is considered excellent for injection molding. H1 utilization was 69%, with the Q2 dip to 63% from 74% in Q1. Management did not break out utilization by business segment.
- Patent enforcement: No compensation received, but the company made two or three competing airing companies stop production and seized their molds.
- Export exposure minimal: USA exports are negligible at ₹2-₹3 crores per annum; tariff impact managed by a 4%-5% price dip. No orders cancelled.
- Pump business: Not gaining major traction; still marginally positive at ₹30-₹40 lakhs per month.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pharma revenue | ₹35-₹37 crores (exceeding ₹35 crore target) | FY26 |
| Pharma revenue | ₹55-₹60 crores | FY27 |
| Pharma revenue | ₹80-₹90 crores (40%-50% growth) | FY28 |
| Volume growth | ~12% volume growth; 12-15% sale value growth | FY26 |
| F&F growth | 15%-20% growth maintained | Ongoing |
| EBITDA per kg | ₹40-₹41 in H2; full year ~₹40.7-₹41 | FY26 |
| Paint volumes | Return to 4,800-5,000 tons per quarter | Once rains subside |
| Grasim full-year volumes | 6,000-6,500 tons | FY26 |
| Panipat F&F major contract | At least ₹4-₹5 crores turnover from one client | FY27 |
| Panipat sweet pack contracts | Numbers to add from February onwards | Q4 FY26 |
| Pharma capacity | Step up to ~2,500 tons | During FY27 |
| Pharma new Greenfield facility | Operational | July-August FY27 |
| Capex | ~₹100-₹105 crores | FY26 |
| Q4 volume growth | Double-digit growth | Q4 FY26 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Sales value growth | 9.65% YoY |
| Volume growth | ~7% YoY |
| EBITDA growth | 8.37% YoY |
| EBITDA per kg | ₹39.4, up from ₹36.38 in Q2 FY25 |
| H1 EBITDA per kg | ₹40.6, up from ₹36.73 in H1 FY25 |
| H1 EBITDA growth | 10.5% YoY |
| H1 sale value growth | 13.88% YoY |
| H1 volume growth | ~12% YoY |
| Capacity utilization | 63%, down from 74% in Q1 FY26 |
| Pharma sales | ₹10.8 cr, up 46% QoQ value and 35% QoQ tonnage |
| Paint volume | 4,845 tons, down from 5,593 tons in Q1 FY26 |
| Paint turnover growth | 2.6% YoY; volume growth 3% YoY |
| Food and FMCG volume growth | 19% YoY |
| Lubricants growth | down ~13% YoY |
| IML and HDL volume share | 75.11%, up from 75.02% in Q1 FY26 |
| CAPEX expected for FY26 | ₹100-₹105 cr, down from ~₹140 cr average last 3 years |
| Full-year EBITDA per kg guidance | ₹40.7-₹41, up from ₹37.6 in FY25 |